JP4958785B2 - 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用 - Google Patents

複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用 Download PDF

Info

Publication number
JP4958785B2
JP4958785B2 JP2007532640A JP2007532640A JP4958785B2 JP 4958785 B2 JP4958785 B2 JP 4958785B2 JP 2007532640 A JP2007532640 A JP 2007532640A JP 2007532640 A JP2007532640 A JP 2007532640A JP 4958785 B2 JP4958785 B2 JP 4958785B2
Authority
JP
Japan
Prior art keywords
alkyl
group
radical
hydrogen
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007532640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513504A5 (enExample
JP2008513504A (ja
Inventor
ラジェンダー カンボジ，
ザイホイ チャン，
チーアン−ミン フ，
バンドナ ライナ，
サーグェイ スビリドフ，
ビシュヌマーシー コドゥムル，
ナガスリー チャッカ，
シーフェン リュー，
シャオイー サン，
デュアンチー フー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of JP2008513504A publication Critical patent/JP2008513504A/ja
Publication of JP2008513504A5 publication Critical patent/JP2008513504A5/ja
Application granted granted Critical
Publication of JP4958785B2 publication Critical patent/JP4958785B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007532640A 2004-09-20 2005-09-20 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用 Expired - Fee Related JP4958785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61164304P 2004-09-20 2004-09-20
US60/611,643 2004-09-20
PCT/US2005/033801 WO2006101521A2 (en) 2004-09-20 2005-09-20 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors

Publications (3)

Publication Number Publication Date
JP2008513504A JP2008513504A (ja) 2008-05-01
JP2008513504A5 JP2008513504A5 (enExample) 2008-10-16
JP4958785B2 true JP4958785B2 (ja) 2012-06-20

Family

ID=37024256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007532640A Expired - Fee Related JP4958785B2 (ja) 2004-09-20 2005-09-20 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用

Country Status (10)

Country Link
US (2) US7592343B2 (enExample)
EP (2) EP1804799B1 (enExample)
JP (1) JP4958785B2 (enExample)
CN (1) CN101083993A (enExample)
AR (1) AR051093A1 (enExample)
AU (1) AU2005329423A1 (enExample)
BR (1) BRPI0515482A (enExample)
CA (1) CA2580857A1 (enExample)
TW (1) TW200626139A (enExample)
WO (1) WO2006101521A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
JP4958787B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
CA2580856A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) * 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CN101083986A (zh) 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
TW200826936A (en) 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
GB0625605D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625654D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625604D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625594D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
WO2008096746A1 (ja) 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited スピロ化合物およびその用途
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
EP2142529B1 (en) * 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
JP2010524987A (ja) 2007-04-27 2010-07-22 サノフィ−アベンティス ２−ヘテロアリール−ピロロ［３，４−ｃ］ピロール誘導体及びｓｃｄ阻害剤としてのそれらの使用
US7842696B2 (en) 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
GB0714129D0 (en) * 2007-07-19 2007-08-29 Smithkline Beecham Corp compounds
GB0715055D0 (en) * 2007-08-02 2007-09-12 Smithkline Beecham Corp Compounds
GB0722075D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
CA2740389A1 (en) * 2008-10-15 2010-05-20 Gilead Sciences, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
WO2010094120A1 (en) 2009-02-17 2010-08-26 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2750635A1 (en) * 2009-02-23 2010-08-26 Merck Canada Inc. Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8383643B2 (en) 2009-07-28 2013-02-26 Merck Canada Inc. Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
EP2475367A1 (en) 2009-09-10 2012-07-18 Centre National De La Recherche Scientifique NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
RS55701B1 (sr) 2011-06-22 2017-07-31 Purdue Pharma Lp Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
WO2013134546A1 (en) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
MX2014014174A (es) 2012-05-22 2015-07-06 Hoffmann La Roche Inhibidores selectivos de celulas no diferenciadas.
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
CN112204017B (zh) * 2018-04-27 2024-08-20 国立大学法人大阪大学 苯并异噁唑化合物
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (303)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985657A (en) 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
DE1670684A1 (de) * 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US3830924A (en) 1966-12-23 1974-08-20 American Cyanamid Co Substituted nitroimidazolyl-thiadiazoles as growth promoting agents
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
DE2427943C2 (de) 1974-06-10 1984-08-02 Dr. Karl Thomae Gmbh, 7950 Biberach Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2516040C2 (de) * 1974-06-10 1984-12-20 Dr. Karl Thomae Gmbh, 7950 Biberach Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
NL171985C (nl) 1976-02-10 1983-06-16 Rhone Poulenc Ind Werkwijze voor het bereiden van preparaten met werking tegen schistosomiasis, de aldus verkregen gevormde preparaten en werkwijze voor het bereiden van 1,2-dithioolverbindingen.
ATE3294T1 (de) 1978-10-02 1983-05-15 Gruppo Lepetit S.P.A. 6-aminosubstituierte n-pyrrolyl-3-pyridazinamine, deren herstellung und sie enthaltende pharmazeutische antihypertensive zusammensetzungen.
US4247551A (en) * 1979-09-17 1981-01-27 Gruppo Lepetit S.P.A. N-Pyrrolyl-pyridazineamines and their use as antihypertensive agents
FI70411C (fi) 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
CH653021A5 (fr) * 1981-04-24 1985-12-13 Delalande Sa Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
US4439606A (en) 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
CH655103A5 (de) 1983-03-11 1986-03-27 Sandoz Ag Azolderivate, verfahren zu ihrer herstellung und ihre verwendung.
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
MA20387A1 (fr) * 1984-03-26 1985-10-01 Janssen Pharmaceutica Nv Pyridazinamines utiles comme agents anti-viraux et procede pour leur preparation
EP0200024B1 (de) 1985-04-30 1992-07-01 ARZNEIMITTELWERK DRESDEN GmbH 3-Cyan-pyridine, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
DE3536030A1 (de) 1985-10-09 1987-04-09 Thomae Gmbh Dr K Verwendung von benzimidazolen zur behandlung der migraene
AU1704588A (en) 1987-04-03 1988-11-02 Upjohn Company, The Amino-9,10-secosteroids
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
DE3827599A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Verwendung von optisch aktiven tetrahydrofuran-2-carbonsaeureestern als dotierstoffe in fluessigkristallmischungen, diese enthaltende fluessigkristallmischungen und neue optisch aktive tetrahydrofuran-2-carbonsaeureester
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
MX9203454A (es) 1989-12-28 1992-08-01 Upjohn Co Compuestos anti sida diaromaticos substituidos.
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5166147A (en) 1990-07-09 1992-11-24 The Du Pont Merck Pharmaceutical Company 4-heteroaryl-and 4-aryl-1,4-dihydropyridine, derivatives with calcium agonist and alpha1 -antagonist activity
EP0471201A1 (de) 1990-07-21 1992-02-19 Hoechst Aktiengesellschaft Neue Oxazolidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen
DE4031000A1 (de) 1990-10-01 1992-04-09 Hoechst Ag 4- oder 5-substituierte pyridin-2-carbonsaeuren, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
IT1245712B (it) 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
EP0520292A1 (de) 1991-06-19 1992-12-30 Hoechst Aktiengesellschaft Chirale Azetidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
KR100236808B1 (ko) 1991-07-03 2000-02-01 로렌스 티. 마이젠헬더 에이즈 치료약제로서의 치환된 인돌
EP0524146A1 (de) * 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9117639D0 (en) 1991-08-15 1991-10-02 Ici Plc Therapeutic compounds
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
JPH05345780A (ja) 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
WO1993014077A1 (en) 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
EP0630370A1 (en) 1992-03-11 1994-12-28 E.I. Du Pont De Nemours And Company Fungicidal oxazolidinones
HU209678B (en) 1992-06-09 1994-10-28 Richter Gedeon Vegyeszet Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them
IT1255704B (it) 1992-09-30 1995-11-10 Boehringer Mannheim Italia Ammine eterocicliche utili nella terapia dell'asma e dell'infiammazione delle vie aeree
DE4236106A1 (de) 1992-10-26 1994-04-28 Hoechst Ag Azaaromatische Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung in flüssigkristallinen Mischungen
US5494908A (en) 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
US5380726A (en) 1993-01-15 1995-01-10 Ciba-Geigy Corporation Substituted dialkylthio ethers
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP3377826B2 (ja) 1993-05-06 2003-02-17 ヘキスト・アクチェンゲゼルシャフト 液晶組成物に使用するための新規化合物
US5547605A (en) 1993-12-15 1996-08-20 Hoechst Aktiengesellschaft 2-Aryloxytetrafluoropropionic esters, process for their preparation, and their use in liquid-crystalline mixtures
DE4343286A1 (de) 1993-12-17 1995-06-22 Hoechst Ag Heteroaromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
DE19502178A1 (de) 1994-01-27 1995-08-03 Hoechst Ag Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Vorprodukte zur Herstellung von Flüssigkristallen
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE4423044A1 (de) 1994-07-01 1996-01-04 Hoechst Ag 1-(3-Alkyloxiran-2-yl)alkylester mesogener Carbonsäuren und ihre Verwendung in flüssigkristallinen Mischungen
US5571811A (en) 1994-07-12 1996-11-05 Janssen Pharmaceutica N.V. Sulfonamide derivatives of azolones
US5607932A (en) 1994-07-12 1997-03-04 Janssen Pharmaceutica N.V. Heterocyclic derivatives of azolones
US5637592A (en) 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
WO1996011210A1 (en) 1994-10-07 1996-04-18 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
DE19517025A1 (de) 1995-05-10 1996-11-14 Hoechst Ag Trifluortetrahydroisochinolin-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517038A1 (de) 1995-05-10 1996-11-14 Hoechst Ag 1,8-Difluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517060A1 (de) 1995-05-10 1996-11-14 Hoechst Ag 1-Fluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517051A1 (de) 1995-05-10 1996-11-14 Hoechst Ag 1-Fluor-6,7-dihydro-5H-isochinolin-8-on-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517056A1 (de) 1995-05-10 1996-11-14 Hoechst Ag 1-Fluor-5,6,7,8-tetrahydroisochinolin-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
ZA969622B (en) 1995-12-13 1998-05-15 Upjohn Co Oxazolidinone antibacterial agents having a six-membered heteroaromatic ring.
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
DE19614204A1 (de) 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
GB9614238D0 (en) * 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
DE19630068A1 (de) 1996-07-25 1998-01-29 Basf Ag Neue flüssigkristalline Verbindungen und deren Vorprodukte
CA2266519C (en) 1996-10-02 2007-01-23 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
DE59707681D1 (de) 1996-10-28 2002-08-14 Rolic Ag Zug Vernetzbare, photoaktive Silanderivate
ZA98376B (en) 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
WO1999000386A1 (en) 1997-06-27 1999-01-07 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
EP0927992A4 (en) 1997-07-17 1999-09-15 Sony Corp MAGNETIC RECORDING MEDIUM AND MAGNETIC RECORDING / REPRODUCING DEVICE COMPRISING SAME
ES2125206B1 (es) 1997-07-21 1999-11-16 Esteve Labor Dr Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
SE9703377D0 (sv) 1997-09-18 1997-09-18 Astra Ab New compounds
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
KR100607838B1 (ko) 1997-10-27 2006-08-04 뉴로서치 에이/에스 니코틴 작용성 아세틸콜린 수용체상의 콜린 작용성 리간드로서의 호모피페라진 유도체 및 이를 포함하는 약제학적 조성물
AU1692399A (en) 1997-12-26 1999-07-19 Mochida Pharmaceutical Co., Ltd. Aromatic compounds having cyclic amino or salts thereof
PT1054874E (pt) 1998-02-13 2003-01-31 Upjohn Co Derivados de aminofenil-isoxazolina substituidos uteis como anti-microbianos
JP2002504550A (ja) 1998-02-25 2002-02-12 ファルマシア・アンド・アップジョン・カンパニー 抗微生物剤として有用な置換アミノメチルイソオキサゾリン誘導体
ATE229945T1 (de) 1998-03-19 2003-01-15 Upjohn Co Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole
ES2325140T3 (es) * 1998-04-20 2009-08-26 ABBOTT GMBH & CO. KG Amidas sustituidas con heterociclos como inhibidores de la calpaina.
EP1076648B1 (de) 1998-04-29 2006-07-12 MERCK PATENT GmbH Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten
KR100579792B1 (ko) 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
EP1082323A2 (en) 1998-06-05 2001-03-14 AstraZeneca UK Limited Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
GB9812019D0 (en) 1998-06-05 1998-07-29 Zeneca Ltd Chemical compounds
DE69919361T2 (de) * 1998-08-25 2005-09-08 Ortho-Mcneil Pharmaceutical, Inc. Pyridyl-ether und -thioether als nikotin-acetylcholin-rezeptorliganden und ihre therapeutische anwendung
EP1119568B1 (en) 1998-10-09 2004-02-18 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
ATE256128T1 (de) 1998-10-21 2003-12-15 Takeda Chemical Industries Ltd Kondensierte pyridazinderivate, verfahren zu ihrer herstellung und ihre anwendung
EP1126833A4 (en) 1998-10-29 2004-09-08 Trega Biosciences Inc OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES
EP1135129A1 (en) 1998-12-02 2001-09-26 Novo Nordisk A/S Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
AU2319100A (en) 1999-01-28 2000-08-18 Nippon Shinyaku Co. Ltd. Amide derivatives and drug compositions
EP1147112B1 (en) 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
AU4166400A (en) 1999-02-11 2000-08-29 Cor Therapeutics, Inc. Alkenyl and alkynyl compounds as inhibitors of factor xa
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
TR200102817T2 (tr) 1999-03-12 2002-05-21 Boehringer Ingelheim Pharmaceuticals, Inc. Antiinflamatuar ajanlar olarak faydalı bileşikler
ATE329596T1 (de) 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
BR0009650A (pt) 1999-04-09 2002-01-02 Meiji Seika Kaisha Composto, composição farmacêutica, processos para inibir a secreção de uma lipoproteìna contendo apolipoproteìna b, para inibir a biossìntese de triglicerìdeos e para prevenir ou tratar hiperlipidemia, doenças arterioscleróticas e pancreatite, e, uso do composto
FR2792314B1 (fr) 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2935200A (en) 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
DE19922723A1 (de) 1999-05-18 2000-11-23 Clariant Gmbh Aktivmatrix-Displays mit hohem Kontrast
WO2000071536A1 (en) 1999-05-20 2000-11-30 E.I. Du Pont De Nemours And Company Heteroaryloxypyrimidine insecticides and acaricides
GB9912413D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
DE19934799B4 (de) 1999-07-28 2008-01-24 Az Electronic Materials (Germany) Gmbh Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten
US6127382A (en) 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
AU6715200A (en) 1999-09-04 2001-04-10 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
US6156758A (en) 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
TR200200763T2 (tr) 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
US6677452B1 (en) 1999-09-30 2004-01-13 Lion Bioscience Ag Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
WO2001032628A1 (en) 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
AU1887401A (en) 1999-12-14 2001-06-25 Nippon Shinyaku Co. Ltd. Medicinal composition
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
US6518285B2 (en) 1999-12-21 2003-02-11 Ortho Mcneil Pharmaceutical, Inc. Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
AU2001243158A1 (en) 2000-02-18 2001-08-27 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
AU2001238424A1 (en) 2000-02-18 2001-08-27 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
EP1315831B8 (en) 2000-02-24 2010-09-01 Xenon Pharmaceuticals Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
YU63802A (sh) 2000-02-25 2005-06-10 F. Hoffmann-La Roche Ag. Modulatori adenozinskih receptora
AU2001245401A1 (en) 2000-03-01 2001-09-12 Sumitomo Pharmaceuticals Company, Limited Hydrazones and analogs as cholesterol lowering agents
JP2003527379A (ja) 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
US7001905B2 (en) 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
US6613917B1 (en) 2000-03-23 2003-09-02 Allergan, Inc. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
PL357678A1 (en) 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
KR100711042B1 (ko) * 2000-04-28 2007-04-24 다나베 세이야꾸 가부시키가이샤 환상 화합물
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
IL153884A0 (en) 2000-07-20 2003-07-31 Neurogen Corp Capsaicin receptor ligands
ATE374765T1 (de) 2000-07-27 2007-10-15 Lilly Co Eli Substituierte heterocyclische amide
HRP20030081A2 (en) 2000-08-08 2005-02-28 Sanofi-Aventis Benzimidazole derivatives, preparation and therapeutic use thereof
EP1184442A1 (en) 2000-08-30 2002-03-06 Clariant International Ltd. Liquid crystal mixture
EP1322767B1 (en) 2000-09-26 2008-07-23 Xenon Pharmaceuticals Inc. Methods and compositions employing a stearoyl-coa desaturase-hscd5
FR2815032B1 (fr) * 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
EP1358177B1 (en) 2000-10-13 2006-08-02 NeuroSearch A/S Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
ATE321024T1 (de) 2000-10-17 2006-04-15 Pharmacia & Upjohn Co Llc Verfahren zur herstellung von oxazolidinonverbindungen
DE10060412A1 (de) 2000-12-05 2002-06-06 Bayer Ag DELTA1-Pyrroline
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
CA2434015A1 (en) 2001-01-16 2002-07-18 Astrazeneca Ab Therapeutic chroman compounds
MXPA03006268A (es) 2001-01-16 2003-09-22 Astrazeneca Ab Compuestos terapeuticos de cromano.
NZ535574A (en) 2001-01-16 2006-07-28 Astrazeneca Ab Therapeutic heterocyclic compounds
ATE455108T1 (de) 2001-02-16 2010-01-15 Aventis Pharma Inc Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
US7126003B2 (en) 2001-03-07 2006-10-24 Daiichi Pharmaceutical Co., Ltd. Method for producing 2-azetidinone derivative
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
MXPA03008180A (es) 2001-03-15 2003-12-12 Astrazeneca Ab Inhibidores de metaloproteinasa.
PT1373218E (pt) 2001-03-29 2008-02-21 Ortho Mcneil Janssen Pharm Derivados de imidazolilo úteis como ligandos do receptor h3 de histamina
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
KR20100008794A (ko) 2001-04-16 2010-01-26 쉐링 코포레이션 Ｃｘｃ-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
CA2446387A1 (en) 2001-05-09 2002-11-14 Sumitomo Chemical Takeda Agro Company, Limited Azole compound, process for producing the same and use thereof
US20030208067A1 (en) 2001-05-30 2003-11-06 Cao Sheldon Xiaodong Inhibitors of protein kinase for the treatment of disease
KR20040010713A (ko) 2001-06-15 2004-01-31 야마노우치세이야쿠 가부시키가이샤 페닐피리딘 카보닐 피페라진 유도체
WO2003003008A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
EP1417188A1 (en) 2001-08-03 2004-05-12 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US20030176437A1 (en) 2001-08-31 2003-09-18 D.M. Watterson Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
WO2003022274A2 (en) 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
FR2829926B1 (fr) 2001-09-26 2004-10-01 Oreal Composition pour la teinture des fibres keratiniques comprenant un colorant diazoique dicationique particulier
US6916812B2 (en) * 2001-10-09 2005-07-12 Bristol-Myers Squibb Company Alpha-aminoamide derivatives as melanocortin agonists
US6824707B2 (en) 2001-10-23 2004-11-30 Clariant International Ltd. Active matrix liquid crystal device and smectic liquid crystal mixture
WO2003035602A1 (en) 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
EP1452525A4 (en) 2001-10-30 2005-01-26 Nippon Shinyaku Co Ltd AMIDE DERIVATIVES AND CORRESPONDING MEDICAMENTS
SE0103648D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
GB0127008D0 (en) 2001-11-09 2002-01-02 Novartis Ag Organic compounds
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
WO2003045921A1 (en) 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
WO2003048140A1 (en) 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
EP1456175A1 (en) 2001-12-07 2004-09-15 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
US20050119251A1 (en) 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7390813B1 (en) * 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US20030166932A1 (en) 2002-01-04 2003-09-04 Beard Richard L. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
PL372390A1 (en) 2002-02-05 2005-07-25 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
WO2003076401A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
JP4648628B2 (ja) 2002-03-13 2011-03-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのカルボニルアミノ誘導体
CA2476583C (en) 2002-03-13 2011-07-05 Kristof Van Emelen Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
AU2003220184A1 (en) 2002-03-20 2003-10-08 Schering Aktiengesellschaft Substituted piperazine antithrombotic pai-1 inhibitors
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
CA2483314A1 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
JP2005289816A (ja) 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
WO2004009587A1 (en) 2002-07-22 2004-01-29 Orchid Chemicals & Pharmaceuticals Ltd Oxazolidinone derivatives as antibacterial agents
AU2003248122A1 (en) 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
US20040072877A1 (en) 2002-07-25 2004-04-15 Ntambi James M. Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
TW200410945A (en) 2002-08-08 2004-07-01 Amgen Inc Vanilloid receptor ligands and their use in treatments"
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
KR20050058507A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
JP2006503827A (ja) 2002-09-06 2006-02-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アレルギー性鼻炎治療用薬剤を製造する目的でインドリル誘導体を用いる使用
MXPA05002332A (es) 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
KR20050057441A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인코포레이티드 전환 성장 인자 억제제로서의 신규한 아이소티아졸 및아이속사졸 화합물
JP2006505570A (ja) 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20040097492A1 (en) 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
DE10254875A1 (de) 2002-11-25 2004-06-03 Bayer Healthcare Ag Phenylsulfoxid und -sulfon-Derivate
JP2004203871A (ja) 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
DE10259382A1 (de) * 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US20050130989A1 (en) 2003-01-28 2005-06-16 Aventis Pharma S. A. N-arylheteroaromatic products compositions containing them and use thereof
TW200505450A (en) 2003-02-03 2005-02-16 Janssen Pharmaceutica Nv Quinoline-derived amide modulators of vanilloid VR1 receptor
GB0302671D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
CN102503903A (zh) 2003-02-07 2012-06-20 詹森药业有限公司 抑制hiv的1,2,4-三嗪
EP1597237B1 (en) 2003-02-07 2016-07-27 Janssen Pharmaceutica NV Pyrimidine derivatives for the prevention of HIV infection
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
EP1594842A1 (en) 2003-02-22 2005-11-16 MERCK PATENT GmbH Cyanopyridone derivatives as liquid crystals
DE602004017703D1 (de) 2003-02-24 2008-12-24 Arena Pharm Inc Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US7160886B2 (en) 2003-03-03 2007-01-09 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
KR100824193B1 (ko) 2003-04-29 2008-04-21 화이자 인코포레이티드 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
DE10322408A1 (de) 2003-05-16 2004-12-02 Degussa Ag Stickstoffhaltige monodentate Phosphine und deren Verwendung in der Katalyse
PE20050226A1 (es) 2003-06-04 2005-05-18 Aventis Pharma Sa Productos aril-heteroaromaticos y composiciones que los contienen
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
WO2004114118A1 (ja) 2003-06-23 2004-12-29 Sharp Kabushiki Kaisha 情報処理装置、集線装置、集線装置を備えたネットワーク情報処理システム、情報処理プログラムおよび記録媒体
US7595316B2 (en) * 2003-06-27 2009-09-29 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
WO2005003087A2 (en) 2003-07-01 2005-01-13 Orchid Chemicals And Pharmaceuticals Ltd. Oxazole derivatives as antibacterial agents
NZ545058A (en) 2003-07-16 2008-05-30 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
ES2317031T3 (es) 2003-07-16 2009-04-16 Janssen Pharmaceutica Nv Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3.
WO2005009980A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
FR2857966A1 (fr) 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
TW200523262A (en) 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
WO2005011654A2 (en) 2003-07-29 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
MXPA06001053A (es) 2003-07-29 2006-04-11 Novo Nordisk As Piridazinil-piperazinas y su uso como ligandos del receptor de histamina h3.
KR20060037410A (ko) 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피리다진 유도체 및 그의 치료제로서의 용도
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
ES2397389T3 (es) 2003-07-30 2013-03-06 Xenon Pharmaceuticals Inc. Derivados de piridilo y su uso como agentes terapéuticos
KR20060037409A (ko) 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피페라진 유도체 및 그의 치료제로서의 용도
EP2316827B1 (en) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
NZ544820A (en) 2003-08-11 2009-02-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
EP1657240A4 (en) 2003-08-18 2009-04-08 Fujifilm Finechemicals Co Ltd PYRIDYLTETRAHYDROPYRIDINE, PYRIDYLPIPERIDINE AND METHOD FOR THE PRODUCTION THEREOF
EP1658291B1 (en) 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
US20070082908A1 (en) * 2003-08-29 2007-04-12 Dainippon Sumitomo Pharma Co., Ltd. Bicycle pyrazole derivative
EP1663232B1 (en) 2003-09-09 2007-10-03 F. Hoffmann-La Roche Ag 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
CN100522171C (zh) 2003-09-09 2009-08-05 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂、用于治疗精神病的1-苯甲酰基哌嗪衍生物
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
ES2361835T3 (es) 2003-09-25 2011-06-22 Janssen Pharmaceutica Nv Derivados de purina inhibidores de la replicación del hiv.
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
AR047759A1 (es) 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
WO2005034952A2 (en) 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
FR2860793A1 (fr) 2003-10-14 2005-04-15 Entomed Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
BRPI0415851A (pt) 2003-10-24 2007-01-02 Solvay Pharm Gmbh utilizações médicas de compostos que apresentam atividade antagonìstica de cb1 e tratamento de combinação envolvendo os referidos compostos
US20050124660A1 (en) 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
WO2005044192A2 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
GB0327323D0 (en) 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
CA2550596C (en) 2003-12-18 2011-03-15 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
AP2331A (en) 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
US7345043B2 (en) 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
FR2868780B1 (fr) 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
EP1758895A1 (en) 2004-06-17 2007-03-07 Wyeth a Corporation of the State of Delaware Gonadotropin releasing hormone receptor antagonists
BRPI0418939A (pt) 2004-07-06 2008-04-08 Xenon Pharmaceuticals Inc derivados de nicotinamida e sua utilização como agentes terapêuticos
WO2006033943A2 (en) 2004-09-17 2006-03-30 Exelixis, Inc Pyrazole kinase modulators and methods of use
JP4958787B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101083986A (zh) 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
ATE472327T1 (de) 2005-01-07 2010-07-15 Hoffmann La Roche Ä4-(heteroaryl)piperazin-1-ylü-(2,5-substituier e phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1902051A1 (en) 2005-06-09 2008-03-26 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US7662819B2 (en) * 2007-04-09 2010-02-16 Gilead Palo Alto, Inc. Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors
UA100192C2 (en) * 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
US20090306090A1 (en) 2009-12-10
EP2269610A2 (en) 2011-01-05
TW200626139A (en) 2006-08-01
JP2008513504A (ja) 2008-05-01
EP1804799A2 (en) 2007-07-11
US7592343B2 (en) 2009-09-22
WO2006101521A2 (en) 2006-09-28
CN101083993A (zh) 2007-12-05
CA2580857A1 (en) 2006-09-28
EP1804799B1 (en) 2013-08-21
EP2269610A3 (en) 2011-03-09
AU2005329423A1 (en) 2006-09-28
US8026360B2 (en) 2011-09-27
AR051093A1 (es) 2006-12-20
WO2006101521A3 (en) 2006-12-28
BRPI0515482A (pt) 2008-07-22
US20080125434A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
JP5149009B2 (ja) ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
JP4958787B2 (ja) ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
JP5080256B2 (ja) 二環式複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼ（ＳＣＤ）のインヒビターとしてのそれらの使用
JP5043668B2 (ja) 複素環誘導体および治療薬としてのそれらの使用
JP2008513504A (ja) 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
JP5094398B2 (ja) 複素環式誘導体およびステアロイル−ＣｏＡデサチュラーゼのメディエータとしてのそれらの使用
JP4958784B2 (ja) ステアロイル−ＣｏＡデサチュラーゼ酵素によって媒介される疾患の処置のための複素環誘導体
JP4884219B2 (ja) ピリジル誘導体および治療剤としてのその用途
JP4831577B2 (ja) ピリダジン誘導体および治療剤としての用途
JP4838128B2 (ja) ピペラジン誘導体および治療剤としてのその用途
JP4958786B2 (ja) 複素環誘導体および治療薬としてのそれらの使用
JP2008513515A (ja) 複素環誘導体および治療薬としてのそれらの使用
JP2008513505A5 (enExample)
JP2007500719A (ja) ピリジル誘導体および治療剤としてのその用途
MX2007003323A (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120302

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120319

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150330

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees